Browsing Tag
Apretude
3 posts
GSK locks in ViiV Healthcare majority as Shionogi doubles down and Pfizer exits with $1.8bn
GSK retains 78.3% of ViiV Healthcare as Shionogi doubles its stake to 21.7% for $2.125 bn and Pfizer exits. Read the full strategic analysis.
GSK FY2025 results show momentum in HIV and oncology while vaccines and general medicines face pressure
GSK’s FY2025 core EPS grew 12 percent with strong Specialty Medicines performance. Find out how the company is planning to sustain momentum in 2026.
EC approves Cabotegravir LA by ViiV Healthcare for HIV prevention
ViiV Healthcare, majorly owned by GSK with Pfizer and Shionogi as shareholders, announced that the European Commission (EC)…